GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (NAS:NRXP) » Definitions » Piotroski F-Score
中文

NRX Pharmaceuticals (NRX Pharmaceuticals) Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2021. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NRX Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for NRX Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

NRXP' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 3
Current: 3

During the past 4 years, the highest Piotroski F-Score of NRX Pharmaceuticals was 3. The lowest was 1. And the median was 2.


NRX Pharmaceuticals Piotroski F-Score Historical Data

The historical data trend for NRX Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NRX Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 1.00 3.00

NRX Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.00 N/A 3.00 2.00 3.00

Competitive Comparison

For the Biotechnology subindustry, NRX Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NRX Pharmaceuticals Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -11.039 + -8.717 + -6.062 + -4.332 = $-30.15 Mil.
Cash Flow from Operations was -6.089 + -7.812 + -4.564 + -3.192 = $-21.66 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(25.816 + 21.78 + 19.809 + 13.11 + 7.315) / 5 = $17.566 Mil.
Total Assets at the begining of this year (Dec22) was $25.82 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $6.88 Mil.
Total Current Liabilities was $19.05 Mil.
Net Income was -13.448 + -6.982 + -9.083 + -10.241 = $-39.75 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(32.729 + 43.601 + 32.433 + 24.824 + 25.816) / 5 = $31.8806 Mil.
Total Assets at the begining of last year (Dec21) was $32.73 Mil.
Long-Term Debt & Capital Lease Obligation was $2.82 Mil.
Total Current Assets was $25.80 Mil.
Total Current Liabilities was $15.59 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NRX Pharmaceuticals's current Net Income (TTM) was -30.15. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NRX Pharmaceuticals's current Cash Flow from Operations (TTM) was -21.66. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-30.15/25.816
=-1.16788038

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-39.754/32.729
=-1.21464145

NRX Pharmaceuticals's return on assets of this year was -1.16788038. NRX Pharmaceuticals's return on assets of last year was -1.21464145. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NRX Pharmaceuticals's current Net Income (TTM) was -30.15. NRX Pharmaceuticals's current Cash Flow from Operations (TTM) was -21.66. ==> -21.66 > -30.15 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0/17.566
=0

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=2.822/31.8806
=0.08851778

NRX Pharmaceuticals's gearing of this year was 0. NRX Pharmaceuticals's gearing of last year was 0.08851778. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=6.884/19.048
=0.36140277

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=25.795/15.585
=1.6551171

NRX Pharmaceuticals's current ratio of this year was 0.36140277. NRX Pharmaceuticals's current ratio of last year was 1.6551171. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NRX Pharmaceuticals's number of shares in issue this year was 8.07. NRX Pharmaceuticals's number of shares in issue last year was 6.647. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

NRX Pharmaceuticals's gross margin of this year was . NRX Pharmaceuticals's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/25.816
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/32.729
=0

NRX Pharmaceuticals's asset turnover of this year was 0. NRX Pharmaceuticals's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NRX Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

NRX Pharmaceuticals  (NAS:NRXP) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NRX Pharmaceuticals Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NRX Pharmaceuticals (NRX Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.
Executives
Richard Clavano Narido officer: Interim CFO 12 HANSEN CT, MORAGA CA 94556
Aaron Gorovitz director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Chaim Hurvitz director C/O GALMED PHARMACEUTICALS LTD., 8 SHAUL, HAMELECH BLVD, AMOT HAMISHPAT BLDG., TEL AVIV L3 64733
Jonathan C Javitt director, 10 percent owner, officer: Chief Scientist 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078
Stephen H Willard director, officer: Chief Executive Officer 1201 ORANGE STREET, SUITE 600, WILMINGTON DE 19801
Daniel C. Javitt 10 percent owner 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Patrick John Flynn director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Ira S Strassberg officer: Chief Financial Officer C/O CONTINENTAL BUILDING PRODUCTS, 12950 WORLDGATE DRIVE, HERNDON VA 20170
Robert Besthof officer: Chief Comm. & Patient Officer 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Alessandra Daigneault officer: General Counsel & Secretary 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Herbert Raymond Mcmaster director C/O ZOOM VIDEO COMMUNICATIONS, INC., 55 ALMADEN BOULEVARD, 6TH FLOOR, SAN JOSE CA 95113
Sharon Glied director 1201 NORTH MARKET STREET, SUITE 111, WILMINGTON DE 19801
Richard Ackerman director, 10 percent owner, officer: President & CEO 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483
Big Rock Partners Sponsor, Llc 10 percent owner 2645 N. FEDERAL HIGHWAY, SUITE 230, DELRAY BEACH FL 33483